SynthesisJournal of global health2026
National, regional and provincial prevalence of carotid atherosclerosis and carotid plaque in Chinese adults: an updated systematic review and modelling analysis.
Synthesis in Journal of global health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Carotid atherosclerosis (CAS), a major contributor to cardiovascular morbidity in China, exhibits substantial geographic disparities that remain unquantified at the provincial level. We aimed to provide updated national, regional, and provincial prevalence of CAS or carotid plaque (CP) among Chinese adults aged 30-79 years. Methods: We searched CNKI, Wanfang, China Science and Technology Journal Database (VIP), PubMed, Embase, and MEDLINE for articles published after 2010 that reported on the prevalence of CAS or CP in the general Chinese population. We used a multilevel mixed-effects meta-regression model to estimate the national age- and sex-specific prevalence of CAS and CP. We assessed the relationships of associated factors with CAS and CP using random-effects meta-analysis. The pooled odds ratios were then incorporated into 'associated factor-based' model, alongside provincial-level associated factor data, to estimate national case numbers across provinces. Results: Based on data from 82 articles, we estimated the overall prevalences of CAS and CP to be 36.35% (95% confidence interval (CI) = 29.74-43.44) and 26.27% (95% CI = 23.17-29.59), respectively. We noted associations between high prevalence and advancing age, with males having a higher prevalence across the whole age spectrum compared to females. A total of 320.25 million (95% CI = 262.03-382.72) and 231.48 million (95% CI = 204.19-260.70) population aged 30-79 years were affected by CAS and CP in mainland China. Current smoking, hypertension, and diabetes were associated with CAS and CP, with dyslipidaemia only associated with CP. Northeast China recorded the highest prevalence of CAS (39.31%; 95% CI = 32.25-46.81) and CP (28.56%; 95% CI = 25.21-32.13) in 2020. Sichuan Province had the highest prevalence of both CAS (42.14%; 95% CI = 34.79-49.92) and CP (30.77%; 95% CI = 27.26-34.50), while Tibet showed the lowest (CAS: 26.80%; 95% CI = 21.35-32.92; CP: 18.74%; 95% CI = 16.33-21.39). Conclusions: CAS and CP are highly prevalent in China, with substantial age trends, sex differences, and regional disparities. Targeted prevention strategies and evidence-based resource allocation are needed to manage the high burden of CAS and CP and their associated factors. Registration: PROSPERO: CRD420251033132.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.